Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.

A method for preparing bio adipic acid includes steps of (a) preparing a glucaric acid potassium salt by mixing and reacting glucose, nitric acid (HNO.sub.3), sodium nitrite (NaNO.sub.2) and potassium hydroxide (KOH), (b) preparing glucamide from the glucaric acid potassium salt prepared in the step (a), (c) preparing 2,4-hexadiene diamide by performing a deoxydehydration reaction on the glucamide prepared in the step (b), (d) preparing adipamide by introducing the 2,4-hexadiene diamide prepared in the step (c), hydrogen and a hydrogenation catalyst to a reactor and performing a hydrogenation reaction, and (e) preparing adipic acid by introducing the adipamide prepared in the step (d) and an aqueous hydrochloric acid solution to a reactor and then performing a hydrolysis reaction at a specific temperature.

Nitroalkene non-steroidal anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of treating inflammation related conditions.

Nitroalkene non-steroidal anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of treating inflammation related conditions.

The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.

##STR00001##

The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3 end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.

The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3 end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.

Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.

Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.

The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.